HEART AND LUNG THERAPIES
Xenios AG – a Fresenius Medical Care Company – is a pioneer in the field of extracorporeal heart and lung support, for new dimensions in patient well-being.
THE XENIOS CONSOLE
Dedicated technology combines both heart and lung support in one single platform – a platform that is universally usable, individual and compatible with applications of our parent company, Fresenius Medical Care.
Novalung therapy allows to mitigate, prevent or replace mechanical ventilation by extracorporeal gas exchange. It enables caregivers to give the lung time to heal and change the therapy environment in the ICU – from CO2 removal to full oxygenation.
Medos is your partner experienced in cardiopulmonary solutions for more than 30 years: highly skilled employees and high-quality manufacturing, for the benefit of cardiac surgeons, perfusionists and patients.
Our internationally acclaimed clinical support team accompanies the clinical application of all Xenios products. Our specialists trained in intensive care are available on a telephone hotline. The clinical support team also provides support on-site in hospitals during initial applications of Novalung products and offers customized training courses.
LEARNING WITH XENIOS
LOOKING FOR FURTHER THERAPY- AND XENIOS PRODUCT INFORMATION?
Join our Xenios Campus to explore various eLearnings for example expert interviews, best-practice-cases, medical knowledge, hands-on-tutorials, priming instructions and more. Of course, free of charge and without obligation.
Merger: Novalung becomes fully integrated within Xenios
Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care.Novalung was established in 2003 and specialises in the treatment ...
Synchronized cardiovascular support now ready for the market
Xenios AG concludes its first clinical study on i-cor Synchronized Cardiac Assist, documenting the safety and feasibility of the synchronized cardiovascular support system.During the “SynCor” trial, a multicentre study treated 47 patients in nine different German clinics using an innovative pulsatile, cardiac-synchronous circulatory support system. The aim of the ...
Relaunch of the Xenios Website – now harmonized with that of its parent, Fresenius Medical Care
The Xenios AG, pioneer in extracorporeal heart and lung support, has restructured its website. Xenios AG has been part of the Fresenius Medical Care Group since 2016 and the new design also serves to bring the company visually in line with the brand image of its parent. www.xenios-ag.comWith this ...
28. September – 02. October
ESICM Lives 2019
ESICM Lives 2019 - European Society Of Intensive Care Medicine - Berlin, Germany